{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:49:40Z","timestamp":1787021380296,"version":"build-2736575974"},"reference-count":38,"publisher":"Japanese Pharmacological Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2009]]},"DOI":"10.1254\/jphs.08r29fm","type":"journal-article","created":{"date-parts":[[2009,2,24]],"date-time":"2009-02-24T00:57:41Z","timestamp":1235437061000},"page":"174-178","source":"Crossref","is-referenced-by-count":32,"title":["Drug Development Targeting the Glycogen Synthase Kinase-3\u03b2 (GSK-3\u03b2)-Mediated Signal Transduction Pathway: Role of GSK-3\u03b2 in Adult Brain"],"prefix":"10.1254","volume":"109","author":[{"given":"Akihiko","family":"Takashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Woodgett JR. Judging a protein by more than its name: GSK-3. Sci STKE. 2001;100:RE12.","DOI":"10.1126\/scisignal.1002001re12"},{"issue":"8","key":"2","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/j.1460-2075.1990.tb07419.x","volume":"9","year":"1990","ISSN":"https:\/\/id.crossref.org\/issn\/0261-4189","issn-type":"print"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 2001;65:391–426.","DOI":"10.1016\/S0301-0082(01)00011-9"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2003.12.004"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis. 2006;9:309–317.","DOI":"10.3233\/JAD-2006-9S335"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets. 2006;7:1421–1434.","DOI":"10.2174\/1389450110607011421"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Lovestone S, Killick R, Di Forti M, Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 2007;30:142–149.","DOI":"10.1016\/j.tins.2007.02.002"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 O’Brien WT, Klein PS. Regulation of glycogen synthase kinase-3 in patients with affective disorders. Biol Psychiat. 2007;61:139–141.","DOI":"10.1016\/j.biopsych.2006.11.008"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1996.tb34411.x"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/0959-4388(92)90034-I"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Goedert M, Spillantini MG, Crowther RA. Tau proteins and neurofibrillary degeneration. Brain Pathol. 1991;1:279–286.","DOI":"10.1111\/j.1750-3639.1991.tb00671.x"},{"issue":"2","key":"12","first-page":"179","volume":"121","author":"IMAHORI K","year":"1997","ISSN":"https:\/\/id.crossref.org\/issn\/0021-924X","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, et al. Activation of tau protein kinase I\/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res. 1998;31:317–323.","DOI":"10.1016\/S0168-0102(98)00061-3"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(92)90774-2"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2006.04139.x"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0500466102"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Boeve BF, Tremont-Lukats IW, Waclawik AJ, Murrell JR, Hermann B, Jack CR Jr, et al. Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. Brain. 2005;128:752–772.","DOI":"10.1093\/brain\/awh356"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)12257-5"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.16.7789"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.01269.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J, Hernandez F. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging. 2006;27:1258–1268.","DOI":"10.1016\/j.neurobiolaging.2005.06.010"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1038\/35017574"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2006.04.012"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2004.09.003"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1126\/science.1086881"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Lee JLC, Milton AL, Everitt BJ. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J Neurosci. 2006;26:10051–10056.","DOI":"10.1523\/JNEUROSCI.2466-06.2006"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Biedenkapp JC, Rudy JW. Context memories and reactivation: constraints on the reconsolidation hypothesis. Behav Neurosci. 2004;118:956–964.","DOI":"10.1037\/0735-7044.118.5.956"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Riccio DC, Moody EW, Millin PM. Reconsolidation reconsidered. Integr Physiol Behav Sci. 2002;37:245–253.","DOI":"10.1007\/BF02734247"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Nader K, Schafe GE, LeDoux JE. The labile nature of consolidation theory. Nat Rev Neurosci. 2000;1:216–219.","DOI":"10.1038\/35044580"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Morris RG, Moser EI, Riedel G, Martin SJ, Sandin J, Day M, et al. Elements of a neurobiological theory of the hippocampus: the role of activity-dependent synaptic plasticity in memory. Philos Trans R Soc Lond B Biol Sci. 2003;358:773–786.","DOI":"10.1098\/rstb.2002.1264"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(97)01189-2"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2007.01.029"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci. 2007;25:81–86.","DOI":"10.1111\/j.1460-9568.2006.05245.x"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1002\/hipo.20107"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2004.02422.x"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1038\/6374"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis. 2003;5:301–308.","DOI":"10.3233\/JAD-2003-5405"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601917"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T11:06:08Z","timestamp":1621422368000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jphs\/109\/2\/109_08R29FM\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.08r29fm","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}